Emma Trawick Roberts,Johanna Quist-Nelson,Elana Jaffe Brotkin,Mehrnaz Salehi,Suneet P Chauhan,Baha M Sibai,Michal Fishel Bartal
{"title":"妊娠期高血压疾病的产后利尿剂:系统回顾和荟萃分析。","authors":"Emma Trawick Roberts,Johanna Quist-Nelson,Elana Jaffe Brotkin,Mehrnaz Salehi,Suneet P Chauhan,Baha M Sibai,Michal Fishel Bartal","doi":"10.1097/aog.0000000000006032","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\r\nTo systematically review the use of diuretics to reduce postpartum hypertension among individuals with hypertensive disorders of pregnancy.\r\n\r\nDATA SOURCES\r\nMEDLINE, EMBASE, CINAHL, and Cochrane Central Register of Controlled Trials were searched through June 2024 (PROSPERO CRD42021288277).\r\n\r\nMETHODS OF STUDY SELECTION\r\nRandomized controlled trials investigating postpartum diuretic use in individuals with hypertensive disorders of pregnancy with 20 or more participants per arm were included. Primary outcomes were hypertension within 2 weeks postpartum and mean systolic or diastolic blood pressure after treatment. Secondary postpartum outcomes included severe maternal morbidity, use of additional antihypertensives, readmission, hypertension at 6 weeks postpartum, and breastfeeding. Risk of bias was assessed with the Cochrane handbook. A random-effects meta-analysis model used the restricted maximum-likelihood estimated treatment effects with relative risk (RR)/mean difference and 95% CIs.\r\n\r\nTABULATION, INTEGRATION, AND RESULTS\r\nOf 469 records reviewed, 10 randomized controlled trials were included (1,815 individuals: 906 intervention, 909 control). Interventions included furosemide (five trials, N=958), torsemide (one trial, N=118), combined furosemide-antihypertensive drug (three trials, N=670), and combined thiazide-angiotensin-converting enzyme inhibitor (one trial, N=67). Seven trials were at high risk of bias. Diuretic use was associated with a reduction in hypertension within 2 weeks postpartum (five trials, N=1,055, pooled RR 0.54, 95% CI, 0.39-0.74; number needed to treat [NNT] 4). There was no difference in mean systolic or diastolic blood pressure after treatment with diuretics; there was also no difference in severe maternal morbidity, readmissions, or any other secondary outcomes. When analysis was restricted to trials at low risk of bias, the reduction in postpartum hypertension was not significant (two trials, N=502, RR 0.62, 95% CI, 0.36-1.09).\r\n\r\nCONCLUSION\r\nDiuretics were associated with a reduction in immediate postpartum hypertension in individuals with hypertensive disorders of pregnancy (NNT 4), although this reduction was not observed when analysis was restricted to trials at low risk of bias. Further studies are needed to assess the role of diuretics in treating postpartum hypertension.\r\n\r\nSYSTEMATIC REVIEW REGISTRATION\r\nPROSPERO, CRD42021288277.","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"746 1","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Postpartum Diuretics for Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-analysis.\",\"authors\":\"Emma Trawick Roberts,Johanna Quist-Nelson,Elana Jaffe Brotkin,Mehrnaz Salehi,Suneet P Chauhan,Baha M Sibai,Michal Fishel Bartal\",\"doi\":\"10.1097/aog.0000000000006032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBJECTIVE\\r\\nTo systematically review the use of diuretics to reduce postpartum hypertension among individuals with hypertensive disorders of pregnancy.\\r\\n\\r\\nDATA SOURCES\\r\\nMEDLINE, EMBASE, CINAHL, and Cochrane Central Register of Controlled Trials were searched through June 2024 (PROSPERO CRD42021288277).\\r\\n\\r\\nMETHODS OF STUDY SELECTION\\r\\nRandomized controlled trials investigating postpartum diuretic use in individuals with hypertensive disorders of pregnancy with 20 or more participants per arm were included. Primary outcomes were hypertension within 2 weeks postpartum and mean systolic or diastolic blood pressure after treatment. Secondary postpartum outcomes included severe maternal morbidity, use of additional antihypertensives, readmission, hypertension at 6 weeks postpartum, and breastfeeding. Risk of bias was assessed with the Cochrane handbook. A random-effects meta-analysis model used the restricted maximum-likelihood estimated treatment effects with relative risk (RR)/mean difference and 95% CIs.\\r\\n\\r\\nTABULATION, INTEGRATION, AND RESULTS\\r\\nOf 469 records reviewed, 10 randomized controlled trials were included (1,815 individuals: 906 intervention, 909 control). Interventions included furosemide (five trials, N=958), torsemide (one trial, N=118), combined furosemide-antihypertensive drug (three trials, N=670), and combined thiazide-angiotensin-converting enzyme inhibitor (one trial, N=67). Seven trials were at high risk of bias. Diuretic use was associated with a reduction in hypertension within 2 weeks postpartum (five trials, N=1,055, pooled RR 0.54, 95% CI, 0.39-0.74; number needed to treat [NNT] 4). There was no difference in mean systolic or diastolic blood pressure after treatment with diuretics; there was also no difference in severe maternal morbidity, readmissions, or any other secondary outcomes. When analysis was restricted to trials at low risk of bias, the reduction in postpartum hypertension was not significant (two trials, N=502, RR 0.62, 95% CI, 0.36-1.09).\\r\\n\\r\\nCONCLUSION\\r\\nDiuretics were associated with a reduction in immediate postpartum hypertension in individuals with hypertensive disorders of pregnancy (NNT 4), although this reduction was not observed when analysis was restricted to trials at low risk of bias. Further studies are needed to assess the role of diuretics in treating postpartum hypertension.\\r\\n\\r\\nSYSTEMATIC REVIEW REGISTRATION\\r\\nPROSPERO, CRD42021288277.\",\"PeriodicalId\":19483,\"journal\":{\"name\":\"Obstetrics and gynecology\",\"volume\":\"746 1\",\"pages\":\"\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrics and gynecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/aog.0000000000006032\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics and gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/aog.0000000000006032","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Postpartum Diuretics for Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-analysis.
OBJECTIVE
To systematically review the use of diuretics to reduce postpartum hypertension among individuals with hypertensive disorders of pregnancy.
DATA SOURCES
MEDLINE, EMBASE, CINAHL, and Cochrane Central Register of Controlled Trials were searched through June 2024 (PROSPERO CRD42021288277).
METHODS OF STUDY SELECTION
Randomized controlled trials investigating postpartum diuretic use in individuals with hypertensive disorders of pregnancy with 20 or more participants per arm were included. Primary outcomes were hypertension within 2 weeks postpartum and mean systolic or diastolic blood pressure after treatment. Secondary postpartum outcomes included severe maternal morbidity, use of additional antihypertensives, readmission, hypertension at 6 weeks postpartum, and breastfeeding. Risk of bias was assessed with the Cochrane handbook. A random-effects meta-analysis model used the restricted maximum-likelihood estimated treatment effects with relative risk (RR)/mean difference and 95% CIs.
TABULATION, INTEGRATION, AND RESULTS
Of 469 records reviewed, 10 randomized controlled trials were included (1,815 individuals: 906 intervention, 909 control). Interventions included furosemide (five trials, N=958), torsemide (one trial, N=118), combined furosemide-antihypertensive drug (three trials, N=670), and combined thiazide-angiotensin-converting enzyme inhibitor (one trial, N=67). Seven trials were at high risk of bias. Diuretic use was associated with a reduction in hypertension within 2 weeks postpartum (five trials, N=1,055, pooled RR 0.54, 95% CI, 0.39-0.74; number needed to treat [NNT] 4). There was no difference in mean systolic or diastolic blood pressure after treatment with diuretics; there was also no difference in severe maternal morbidity, readmissions, or any other secondary outcomes. When analysis was restricted to trials at low risk of bias, the reduction in postpartum hypertension was not significant (two trials, N=502, RR 0.62, 95% CI, 0.36-1.09).
CONCLUSION
Diuretics were associated with a reduction in immediate postpartum hypertension in individuals with hypertensive disorders of pregnancy (NNT 4), although this reduction was not observed when analysis was restricted to trials at low risk of bias. Further studies are needed to assess the role of diuretics in treating postpartum hypertension.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO, CRD42021288277.
期刊介绍:
"Obstetrics & Gynecology," affectionately known as "The Green Journal," is the official publication of the American College of Obstetricians and Gynecologists (ACOG). Since its inception in 1953, the journal has been dedicated to advancing the clinical practice of obstetrics and gynecology, as well as related fields. The journal's mission is to promote excellence in these areas by publishing a diverse range of articles that cover translational and clinical topics.
"Obstetrics & Gynecology" provides a platform for the dissemination of evidence-based research, clinical guidelines, and expert opinions that are essential for the continuous improvement of women's health care. The journal's content is designed to inform and educate obstetricians, gynecologists, and other healthcare professionals, ensuring that they stay abreast of the latest developments and best practices in their field.